**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Badelita Sorina Nicoleta, Fundeni Clinical Institute, Bucharest, Romania

**Main Body of the Abstract**
Aim: Light chain amyloidosis (AL) is an incurable clonal plasma cell disorder characterized by the deposition of immunoglobulin light chain in tissues, resulting in organ dysfunction.
This retrospective, single-center study aims to determine the hematologic response in patients receiving first-line Daratumumab therapy in two different combinations: D-VCD and DRD. DRD protocol was preferred for patients with severe neurological involvement and for those diagnosed before January 2023 when D-VCD was reimbursed in Romania.
Methods: Between January 2021-December 2023, 53 patients were diagnosed with AL Amyloidosis at the Fundeni Clinical Institute, Romania with 38 patients received Daratumumab therapy. Two subgroups were formed: one following D-VCD protocol (n=23) and DRD protocol (n=15).
Results: The median age at diagnosis was 61.5 years (range, 44-77); 25 patients (65%) had ≥3 organ involvement, with cardiac involvement in 21 pts (55%). All patients with severe neurological involvement (n=5, 33.3%) received the DRD regimen (table 1). At 2 months, 88.2% of patients undergoing D-VCD treatment achieved ≥VGPR, while the DRD group reached ≥VGPR in 33.3% of patients (p=0.010, Chi2). For patients receiving DRD, 55.5% and 75% achieved ≥VGPR at 6 and respectively 12 months.
6 patients (15.7%) underwent ASCT, all of whom following D-VCD protocol and currently maintaining ≥VGPR. Median survival for both groups has not been reached without significant group differences.
Conclusions: Despite D-VCD leading a quicker hematologic response, DRd as initial treatment for AL patients achieves deep hematologic responses at 6 and 12 months and may be a practical choice for those with severe neurological involvement.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Badelita Sorina Nicoleta, Fundeni Clinical Institute, Bucharest, Romania

**Main Body of the Abstract**
**Aim**: Light chain amyloidosis (AL) is an incurable clonal plasma cell disorder characterized by the deposition of immunoglobulin light chain in tissues, resulting in organ dysfunction.
This retrospective, single-center study aims to determine the hematologic response in patients receiving first-line Daratumumab therapy in two different combinations: D-VCD and DRD. DRD protocol was preferred for patients with severe neurological involvement and for those diagnosed before January 2023 when D-VCD was reimbursed in Romania.
**Methods**: Between January 2021-December 2023, 53 patients were diagnosed with AL Amyloidosis at the Fundeni Clinical Institute, Romania with 38 patients received Daratumumab therapy. Two subgroups were formed: one following D-VCD protocol (n=23) and DRD protocol (n=15).
**Results**: The median age at diagnosis was 61.5 years (range, 44-77); 25 patients (65%) had ≥3 organ involvement, with cardiac involvement in 21 pts (55%). All patients with severe neurological involvement (n=5, 33.3%) received the DRD regimen (table 1). At 2 months, 88.2% of patients undergoing D-VCD treatment achieved ≥VGPR, while the DRD group reached ≥VGPR in 33.3% of patients (p=0.010, Chi2). For patients receiving DRD, 55.5% and 75% achieved ≥VGPR at 6 and respectively 12 months.
6 patients (15.7%) underwent ASCT, all of whom following D-VCD protocol and currently maintaining ≥VGPR. Median survival for both groups has not been reached without significant group differences.
**Conclusions:** Despite D-VCD leading a quicker hematologic response, DRd as initial treatment for AL patients achieves deep hematologic responses at 6 and 12 months and may be a practical choice for those with severe neurological involvement.



DRD vs D-VCD in patients with newly diagnosed AL amyloidosis PA165 (#483)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.